There are several differentiation protocols established to generate proximal or distal lung cells from iPSCs providing a renewable source of CF patient-derived tissue that can be exploited for HTS of novel CFTR modulators, theratyping and beyond [164,165,166,167,168]. Here, CFTR is linked to cystic fibrosis.